Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Mitigating risk of aldosterone in diabetic kidney disease

    Research output: Contribution to journalReviewResearchpeer-review

  3. Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease

    Research output: Contribution to journalEditorialResearchpeer-review

View graph of relations

Sodium retention and volume overload are main determinants of poor response to RAAS inhibition in patients with diabetes. As volume excess can exist without symptoms, biomarkers are needed to identify a priori which patients are volume overloaded and may experience less benefit from RAAS inhibition. N-terminal pro-brain natriuretic peptide (NT-proBNP) is released in the setting of increased cardiac wall stress and volume overload. We conducted a post-hoc analysis among 5081 patients with type 2 diabetes mellitus participating in the ALTITUDE trial to investigate whether NTproBNP can predict the effects of additional therapy with aliskiren on cardio-renal endpoints. Aliskiren compared to placebo reduced the risk of the primary cardio-renal endpoint events by 20% (95%CI: 16 to 61) and 2% (-42 to 30) in the two lowest NT-proBNP tertiles, and it increased the risk by 25% (-4 to 96) in the highest NT-proBNP tertile (p-value for trend = 0.009). Similar trends were observed for the cardiovascular and ESRD end points. Effects of aliskiren compared to placebo on safety outcomes (hyperkalemia and hospitalization for acute kidney injury) were independent of NT-proBNP. In conclusion, baseline NT-proBNP may be used as a marker to predict the response to aliskiren on cardio-renal outcomes when added to standard therapy with RAAS inhibition. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism Online
Issue number12
Pages (from-to)2899-2904
Number of pages5
Publication statusPublished - Dec 2018

ID: 54755479